Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2

Thrombosis and Haemostasis

Volumn 82, Issue 6, 1999, Pages 1730-1735

  Fernandez Patron, Carlos ^a   Martinez Cuesta, Maria A ^a,b   Salas, Eduardo ^a,b   Sawicki, Grzegorz ^a   Wozniak, Mieczyslaw ^c   Radomski, Marek W ^a   Davidge, Sandra T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Div of Res and Devmt Lácer   (Spain)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Aggregation; MMPs; Platelets; Vascular

Indexed keywords

COLLAGEN; GELATINASE A; GELATINASE B; THROMBIN;

ARTICLE; CELL INTERACTION; CONTROLLED STUDY; ENZYME RELEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

EID: 0032744218     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614906     Document Type: Article

References (30)

1. Ray JM, Stetler-Stevenson, WG. The role of metalloproteinases and their inhibitors in tumor, metastasis, and angiogenesis. Eur Respir J 1994; 7: 2062-72.
2. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opinion in Cell Biol 1995; 7: 728-35.
3. Baramova EN, Bajou K, L'Hoir C, Krell HW, Weidle UH, Noel A, Foidart JM. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 1997; 405: 157-62.
4. Vissers MC, Winterbourn CC. Activation of human neutrophil gelatinase by endogenous serine proteases. Biochem J 1988; 249: 327-31.
5. Desrivieres S, Lu H, Soria C, Legrand Y, Menashi S. Activation of the 92 kDa Type IV collagenase by tissue kallikrein. J Cell Physiol 1993; 157: 587-93.
6. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61-5.
7. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-9.
8. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995; 77: 863-8.
9. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: An emerging pathophysiological paradigm in aortic aneurysm. Circulation 1997; 96: 2115-7.
10. Bramhall SR, Neoptolemos JP, Stamp GWH, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPS) in human pancreatic carcinoma. J Pathology 1997; 187: 347-55.
11. Radomski MW, Zakar T, Salas E. Nitric oxide in platelets. Methods in Enzymology 1996; 269: 88-97.
12. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-8.
13. Radomski MW, Salas E. Biological significance of nitric oxide in platelet function. In: Nitric oxide: a modulator of cell-cell interactions in the microcirculation. Kubes P, ed. Heidelberg: Springer Verlag 1995; 43-74.
14. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J 1992; 288: 93-9.
15. Sawicki G, Matsuzaki A, Janowska-Wieczorek A. Expression of the active form of MMP-2 on the surface of leukemic cells accounts for their in vitro invasion. J Cancer Res Clin Oncol 1998; 124: 245-52.
16. Sawicki G, Sanders EJ, Salas E, Wozniak M, Rodrigo J, Radomski MW. Localization and translocation of MMP-2 during aggregation of human platelets. Thromb Haemost 1998; 80: 836-9.
17. Radomski M, Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb Res 1983; 30: 383-9.
18. Heussen C, Dowle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecylsulfate and copolymerized substrate. Anal Biochem 1980; 102: 196-202.
19. Castellanos-Serra L, Fernandez-Patron C, Hardy E, Huertas V. High yield elution of proteins from SDS-Polyacrylamide gels at the low picomol level. Application to N-terminal sequencing of a scarce protein and to in-solution biological activity analysis of on-gel renatured proteins. J Prot Chem 1997; 16: 415-9.
20. Triebel S. A 25 kDa alpha2-microglobulin-related protein is a component of the 125kDa form of human gelatinase. FEBS Lett 1992; 314: 386-8.
21. Goldberg GI, Strongin A, Collier LE, Genrich LT, Marmer BL. Interaction of 92 kDa, type IV gelatinase with TIMP prevents dimerisation, complex formation, and activation of the proenzyme with stromelysin. J Biol Chem 1992; 267: 4583-91.
22. Chesney CM, Harper E, Colman RW. Human platelet collagenase. J Clin Invest 1974; 53: 1647-54.
23. Leven RM, Yee T. Collagenase production by guinea pig megakaryocytes in vitro. Exp Hematol 1990; 18: 743-7.
24. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
25. Moro MA, Darley-Usmar VM, Goodwin DA, Reed NG, Zamora-Pino R, Feelisch M, Radomski MW, Moncada S. Paradoxical fate and biological action of peroxynitrite on human platelets. PNAS 1994; 91: 6702-6.
26. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathognesis of arteriosclerosis. Basic Res Cardiol 1993; 89: S1:59-70.
27. Brown D, Hibbs MS, Kearney M, Isner JM. Differential expression of 92 kDa gelatinase in primary atherosclerotic versus restenotic coronary-lesions. Am J Cardiol 1997; 79: 878-82.
28. Libby P, Geng Y-J, Sukhova GK, Simon DI, Lee RT, Alexander RW. Clowes A, Tanaka K, Fuster V, Kume N, Suzuki A. Molecular determinants of atherosclerotic plaque vulnerability. Annals of the New York Academy of Sciences 1997; 811: 134-45.
29. Brown PD. In: Matrix metalloproteinases. Parks WC, Mecham RP, eds. San Diego, London: Academic Press 1998: pp.243-61.
30. Thromb Haemost 1999:82: 1736-42